Drug Profile
Research programme: anti-infectives - BioAgency
Alternative Names: NLX TargetLatest Information Update: 17 Jan 2011
Price :
$50
*
At a glance
- Originator BioAgency AG
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections; Parasitic infections
Most Recent Events
- 20 Aug 2007 NLX Target is available for licensing (http://www.bioagency.com)
- 20 Aug 2007 Early research in Bacterial infections in Germany (unspecified route)
- 20 Aug 2007 Early research in Parasitic infections in Germany (unspecified route)